Literature DB >> 23375388

GUCY2C: at the intersection of obesity and cancer.

Gilbert W Kim1, Jieru E Lin, Scott A Waldman.   

Abstract

Guanylyl cyclase C (GUCY2C) has canonical centrality in defense of key intestinal homeostatic mechanisms, encompassing fluid and electrolyte balance, epithelial dynamics, antitumorigenesis, and intestinal barrier function. Recent discoveries expand the homeostatic role of GUCY2C to reveal a novel gut-brain endocrine axis regulating appetite, anchored by hypothalamic GUCY2C which is responsive to intestine-derived uroguanylin. Thus, GUCY2C may represent a new target for anti-obesity pharmacotherapy. Moreover, the coincident regulation of energy balance and tumor suppression by a single hormone receptor system suggests that the GUCY2C axis might contribute to the established relationship between obesity and colorectal cancer. This confluence suggests that hormone supplementation to reconstitute GUCY2C signaling may be an elegant strategy to reverse both pathophysiologic processes.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23375388      PMCID: PMC3617062          DOI: 10.1016/j.tem.2013.01.001

Source DB:  PubMed          Journal:  Trends Endocrinol Metab        ISSN: 1043-2760            Impact factor:   12.015


  74 in total

1.  Insulin, cGMP, and TGF-beta signals regulate food intake and quiescence in C. elegans: a model for satiety.

Authors:  Young-jai You; Jeongho Kim; David M Raizen; Leon Avery
Journal:  Cell Metab       Date:  2008-03       Impact factor: 27.287

2.  Guanylyl cyclase expression in specific sensory neurons: a new family of chemosensory receptors.

Authors:  S Yu; L Avery; E Baude; D L Garbers
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-01       Impact factor: 11.205

Review 3.  Metabolic sensing and the brain: who, what, where, and how?

Authors:  Barry E Levin; Christophe Magnan; Ambrose Dunn-Meynell; Christelle Le Foll
Journal:  Endocrinology       Date:  2011-04-26       Impact factor: 4.736

4.  Diet, drugs and surgery for weight loss.

Authors: 
Journal:  Treat Guidel Med Lett       Date:  2011-04

Review 5.  Corruption of homeostatic mechanisms in the guanylyl cyclase C signaling pathway underlying colorectal tumorigenesis.

Authors:  Peng Li; Scott A Waldman
Journal:  Cancer Biol Ther       Date:  2010-08-11       Impact factor: 4.742

6.  A uroguanylin-GUCY2C endocrine axis regulates feeding in mice.

Authors:  Michael A Valentino; Jieru E Lin; Adam E Snook; Peng Li; Gilbert W Kim; Glen Marszalowicz; Michael S Magee; Terry Hyslop; Stephanie Schulz; Scott A Waldman
Journal:  J Clin Invest       Date:  2011-08-25       Impact factor: 14.808

Review 7.  Regulation of appetite to treat obesity.

Authors:  Gilbert W Kim; Jieru E Lin; Michael A Valentino; Francheska Colon-Gonzalez; Scott A Waldman
Journal:  Expert Rev Clin Pharmacol       Date:  2011-03       Impact factor: 5.045

8.  Topiramate treatment improves hypothalamic insulin and leptin signaling and action and reduces obesity in mice.

Authors:  Andrea M Caricilli; Erica Penteado; Lélia L de Abreu; Paula G F Quaresma; Andressa C Santos; Dioze Guadagnini; Daniella Razolli; Francine C Mittestainer; Jose B Carvalheira; Licio A Velloso; Mario J A Saad; Patricia O Prada
Journal:  Endocrinology       Date:  2012-07-20       Impact factor: 4.736

Review 9.  The obesity epidemic: current and future pharmacological treatments.

Authors:  Karl G Hofbauer; Janet R Nicholson; Olivier Boss
Journal:  Annu Rev Pharmacol Toxicol       Date:  2007       Impact factor: 13.820

10.  Association of GUCY2C expression in lymph nodes with time to recurrence and disease-free survival in pN0 colorectal cancer.

Authors:  Scott A Waldman; Terry Hyslop; Stephanie Schulz; Alan Barkun; Karl Nielsen; Janis Haaf; Christine Bonaccorso; Yanyan Li; David S Weinberg
Journal:  JAMA       Date:  2009-02-18       Impact factor: 56.272

View more
  6 in total

1.  Guanylin and uroguanylin stimulate lipolysis in human visceral adipocytes.

Authors:  A Rodríguez; J Gómez-Ambrosi; V Catalán; S Ezquerro; L Méndez-Giménez; S Becerril; P Ibáñez; N Vila; M A Margall; R Moncada; V Valentí; C Silva; J Salvador; G Frühbeck
Journal:  Int J Obes (Lond)       Date:  2016-04-25       Impact factor: 5.095

2.  Uroguanylin levels in intestine and plasma are regulated by nutritional status in a leptin-dependent manner.

Authors:  C Folgueira; E Sanchez-Rebordelo; S Barja-Fernandez; R Leis; S Tovar; F F Casanueva; C Dieguez; R Nogueiras; L M Seoane
Journal:  Eur J Nutr       Date:  2015-03-06       Impact factor: 5.614

3.  Pilot Study Measuring the Novel Satiety Hormone, Pro-Uroguanylin, in Adolescents With and Without Obesity.

Authors:  Matthew D Di Guglielmo; Dalal Tonb; Zhaoping He; Adebowale Adeyemi; Kenneth L van Golen
Journal:  J Pediatr Gastroenterol Nutr       Date:  2018-03       Impact factor: 2.839

Review 4.  Colorectal cancer immunotherapy.

Authors:  Bo Xiang; Adam E Snook; Michael S Magee; Scott A Waldman
Journal:  Discov Med       Date:  2013-05       Impact factor: 2.970

5.  Circulating Pro-Uroguanylin Levels In Children And Their Relation To Obesity, Sex And Puberty.

Authors:  Cintia Folgueira; Silvia Barja-Fernández; Patricia Gonzalez-Saenz; Cecilia Castelao; Rocío Vázquez-Cobela; Veronica Pena-Leon; Manuel Ruiz-Piñon; Felipe F Casanueva; Carlos Dieguez; Rosaura Leis; Rubén Nogueiras; Luisa M Seoane
Journal:  Sci Rep       Date:  2018-09-28       Impact factor: 4.379

6.  Calorie-induced ER stress suppresses uroguanylin satiety signaling in diet-induced obesity.

Authors:  G W Kim; J E Lin; A E Snook; A S Aing; D J Merlino; P Li; S A Waldman
Journal:  Nutr Diabetes       Date:  2016-05-23       Impact factor: 5.097

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.